ABP-100 / Memorial Sloan-Kettering Cancer Center, Abpro Bio - LARVOL DELTA

Dietary supplementation with antibacterial peptide microcin J25 improved antioxidant capacity and intestinal health of pigeons. (PubMed, Front Vet Sci) - "A total of 28-day-old pigeons were allocated to four groups and fed a basal diet (CON) or a basal diet supplemented with 100, 200, or 300 mg/kg MccJ25 (ABP100, ABP200, and ABP300) for 8 weeks. These findings indicate that MccJ25 supplementation improves systemic metabolism, enhances antioxidant defenses, strengthens intestinal barrier integrity, and ultimately promotes pigeon health and survival. This study supports the application of MccJ25 as a functional feed additive in poultry production."

Journal • CAT • CLDN1 • MUC2 • OCLN • SOD1 • TJP1

VA-ECMO With IABP is Associated With Better Outcome Than VA-ECMO Alone in the Treatment of Cardiogenic Shock in ST-Elevation Myocardial Infarction. (PubMed, J Invasive Cardiol) - "In STEMI complicated by CS, VA-ECMO + IABP leads to a lower observed mortality and higher observed good neurological outcome."

Journal • Cardiovascular • Myocardial Infarction

Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. (PubMed, J Gastrointest Oncol) - "Median doses were NabP 100 mg/m + GEM 600 mg/m IV with a fixed-dose rate infusion (10 mg/m/min). No admissions related to toxicity were found. Our analysis revealed safety with NabP (median dose =100 mg/m) + GEM (median dose =600 mg/m at fixed-dose rate) given predominately biweekly in patients with a baseline elevated total bilirubin (≥2 mg/dL)."

Journal • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Claudin18.2 bispecific T-cell engager for gastric cancer immunotherapy (SITC 2019) - "Their ability to bind to T-cells were comparable to ABP100 [2, 3] suggesting functional monovalent binding to CD3... Lead CLDN18.2 clones, ABP150-1 and ABP150-2 as T-cell engagers showed CLDN18.2 specific binding and functionally weak CD3 binding (in the absence of target ) resulting in strong TDCC response only in the presence of CLDN18.2 tumors. Taken together, we conclude that these two clones are expected to efficiently clear CLDN18.2 tumors without cytokine release syndrome."

IO Biomarker

Novel tetravalent bispecific T-cell engaging antibodies for cancer immunotherapy. (ASCO 2019) - "...In preclinical studies, ABP-100 was compared with a clinical-stage heterodimeric antibody that is monovalent for HER2 and CD3...ABP110 and ABP-150 also demonstrated potent cancer cell killing in vitro. This novel TetraBi antibody format enables concurrent bivalent and monovalent co-engagement of distinct target antigens in tumor microenvironment with promising therapeutic implications. Furthermore, it provides a potentially larger therapeutic index than more traditional bispecific formats that feature monovalent recognition of tumor antigens."